Effectiveness of treatments in Neuromyelitis optica to modify the course of disease in adult patients. Systematic review of literature.-Reference-Cited by-同舟云学术

Effectiveness of treatments in Neuromyelitis optica to modify the course of disease in adult patients. Systematic review of literature.

Published:2021-05 Issue: Volume:50 Page:102869
ISSN:2211-0348
Container-title:Multiple Sclerosis and Related Disorders
language:en
Short-container-title:Multiple Sclerosis and Related Disorders

Author:

Velasco Mario^ORCID,Zarco Luis Alfonso^ORCID,Agudelo-Arrieta Mariana,Torres-Camacho Isabel,Garcia-Cifuentes Elkin^ORCID,Muñoz Oscar^ORCID

Publisher

Elsevier BV

Subject

Clinical Neurology,Neurology,General Medicine

Reference31 articles.

1. Interleukin 6 receptor blockade in patients with neuromyelitis optica nonresponsive to anti-CD20 therapy;Ayzenberg;JAMA Neurol.,2013

2. Controversies in the management of neuromyelitis optica spectrum disorder;Bruscolini;Expert Rev. Neurother.,2019

3. Comparisons of the efficacy and tolerability of mycophenolate mofetil and azathioprine as treatments for neuromyelitis optica and neuromyelitis optica spectrum disorder;Chen;Eur. J. Neurol.,2017

4. Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2/3 trial;Cree;Lancet,2019

5. The efficacy and tolerability of azathioprine for patients with neuromyelitis optica spectrum disorder: a systematic review;Espiritu;Neurology,2019

Cited by 19 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Preferences for neuromyelitis optica spectrum disorder treatments: A conjoint analysis with neurologists in Spain;Multiple Sclerosis and Related Disorders;2024-08

2. Immunosuppressive therapy in elderly patients with neuromyelitis optica spectrum disorder: a retrospective multicentre study;Journal of Neurology, Neurosurgery & Psychiatry;2024-05-22

3. Impact of rituximab treatment regime on time to relapse in aquaporin-4 antibody positive neuromyelitis optica spectrum disorder;Multiple Sclerosis and Related Disorders;2024-05

4. Inebilizumab for neuromyelitis optica spectrum disorders in Italy: a budget impact model;Expert Review of Pharmacoeconomics & Outcomes Research;2023-10-17

5. Delayed diagnosis of the neuromyelitis optica spectrum disorder;Neurology, Neuropsychiatry, Psychosomatics;2023-08-21